Stéphane MOUTEL, PhD, PRINCE2®, PMP®

Stéphane Moutel, PhD, PRINCE2®, PMP® has a diverse and extensive work experience in the pharmaceutical and biotech industries. Stéphane began their career in 1999 as a Research Chemist at the Institut de Chimie Organique et Analytique - ICOA UMR7311. From 2001 to 2004, they worked as a Synthetic API Development Chemist at OM Pharma, where they managed a chemistry research laboratory and coordinated outsourced contracts for chemical development and manufacturing. Stéphane then took on the role of Head of Synthetic Process at OM Pharma from 2004 to 2009, overseeing a chemistry research laboratory and managing the outsourcing of API and analytical development.

In 2009, Stéphane joined Vifor Pharma as the Head of Synthetic Process - Senior Manager, where they managed a chemistry research laboratory and led a team in the chemical and preclinical R&D department. Stéphane also selected appropriate CMOs and managed outsourced chemical development and manufacturing activities for API.

In 2017, Stéphane joined NovImmune as the Head of CMC Project Management, responsible for managing the CMC project schedule for kappa-lambda bispecific antibodies and ensuring effective planning, coordination, and communication. Stéphane also managed the project budget, selected CMOs and CROs for outsourcing activities, and acted as a liaison for external suppliers and stakeholders. From 2019 to 2021, they continued their role as Head of CMC Project Management at NovImmune, further enhancing their responsibilities in project planning, budget management, risk mitigation, and team coordination.

In 2019, Stéphane joined Sobi - Swedish Orphan Biovitrum AB (publ) as the CMC Program Leader, overseeing the CMC projects for all clinical and commercial programs and ensuring effective planning, coordination, and communication. Stéphane also served as the Head of CMC Project Management from 2020 to 2021, where they directly managed a team of CMC Project Managers and coordinators and had responsibilities in external manufacturing, cost management, risk mitigation, and procurement.

Stéphane's most recent role is as a Scientific Advisory Board member at Mablink Bioscience, starting in 2021. Currently, they are also working as a CMC Project Manager at Light Chain Bioscience | Novimmune SA, where they manage CMC projects.

Throughout their career, Stéphane has demonstrated expertise in project management, team leadership, budget management, outsourcing, and coordination with various stakeholders in the pharmaceutical and biotech industries. Their academic background, including a PhD and certifications in PRINCE2® and PMP®, further strengthens their qualifications for these roles.

Stéphane MOUTEL, PhD, PRINCE2®, PMP®, has a diverse educational background. Stéphane began their education in 1988 at Paris-Sud University (Paris XI), where they obtained a DUT in Chemistry from the IUT Orsay. From 1994 to 1997, they pursued further education at Université d'Orléans, earning a Doctor of Philosophy (Ph.D.) in Chemistry and Physicochemistry of biological interest compounds. Following this, from 1998 to 1999, they served as a Postdoctoral Fellow at the University of Exeter, focusing on an undisclosed field of study.

In addition to their academic achievements, Stéphane MOUTEL has also acquired notable certifications. Stéphane obtained the PRINCE2® Foundation certification from AXELOS Global Best Practice in October 2019, demonstrating their proficiency in project management methodologies. Furthermore, they earned the Project Management Professional (PMP)® certification from the Project Management Institute in December 2016, affirming their knowledge and skills in project management practices.